中国肺癌杂志2015，Vol.18Issue(4)：240-244,5.DOI:10.3779/j.issn.1009-3419.2015.04.09
HGF/c-MET抑制剂治疗非小细胞肺癌的研究进展
Research Progress of HGF/c-MET Inhibitor in the Treatment of Non-small Cell Lung Cancer
摘要
Abstract
Molecular targeted therapy has become more and more important in the treatment of non-small cell lung cancer (NSCLC). HGF/c-MET plays the pivotal role in the growth, development and tolerance to epidermal growth fac-tor receptor tyrosine kinase inhibitor of NSCLC. Moreover it has become another heat point in the molecular targeted therapy of NSCLC. c-MET ampliifcation or high expression was deemed to another signiifcant gene modiifcation beyond EGFR and ALK. In the preclinical studies, HGF/c-MET inhibitors have showed the promising anti-tumor effect. Recently, some phase Ⅱ/Ⅲ clinical trials have proved that these inhibitors could improve the survival of patients with NSCLC. Hence we performed this review to elaborate the research progress of c-MET inhibitor in the treatment of NSCLC.关键词
HGF/c-MET/肺肿瘤/抑制剂Key words
HGF/c-MET/Lung neoplasms/Inhibitor引用本文复制引用
蒋涛,周彩存..HGF/c-MET抑制剂治疗非小细胞肺癌的研究进展[J].中国肺癌杂志,2015,18(4):240-244,5.
